The global blood screening market is broadly classified into technology, product & service, end user, and region. 

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042

Blood screening is a medical process in which donated blood is mainly tested for HIV1, HIV2, HBV, HCV, malaria, syphilis, and various other infectious diseases. Donated blood is screened for these infectious diseases to reduce the risk of transfusion-transmitted infections (TTIs).

Based on technology, the market is segmented into NAT, ELISA, rapid tests, western blot assays, and NGS. 

On the basis of product and service, the blood screening market is segmented into reagents & kits, instruments, and software & services.

On the basis of end user, the blood screening market is segmented into blood banks and hospitals. 

On the basis of region, the blood screening market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). 

Browse 97 market data tables 

39 figures

150 pages and in-depth TOC on “Blood Screening Market"

Key players in the blood screening market include Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthineers (Germany), Abbott Laboratories (U.S.), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), and Beckman Coulter, Inc. (U.S.).

Major Market Development:

In June 2016, Grifols and Hologic, Inc. (U.S.) announced the U.S. FDA approval of the Procleix Zika virus blood-screening assay on the Procleix Panther system under the agency's Investigational New Drug (IND) study protocol. This enhanced the company’s portfolio of blood screening products.
In October 2016, Roche announced the FDA approval of the cobas MPX test for use on the cobas 6800 and 8800 Systems. This detects HIV-1, HIV-2, HBV, and HCV in transfused blood products.
In July 2015, Roche announced the market availability of the Elecsys HTLV-I/II immunoassay. This diagnostic test detects antibodies against Human T-lymphotropic virus I & II infections in donated blood and routine diagnostic samples.
Request for Sample @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=267747042

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441